Immunotherapy for Uterine Cervical Cancer

被引：44

作者：

Kagabu, Masahiro ^{[1
]}

Nagasawa, Takayuki ^{[1
]}

Fukagawa, Daisuke ^{[1
]}

Tomabechi, Hidetoshi ^{[1
]}

Sato, Saiya ^{[1
]}

Shoji, Tadahiro ^{[1
]}

Baba, Tsukasa ^{[1
]}

机构：

[1] Iwate Med Univ, Dept Obstet & Gynecol, Sch Med, Morioka, Iwate 0208505, Japan

来源：

HEALTHCARE | 2019年 / 7卷 / 03期

关键词：

cervical cancer; immunotherapy; immune checkpoint inhibitor; EXPRESSION; PD-L1; INHIBITORS; DEATH;

D O I：

10.3390/healthcare7030108

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Cervical cancer is a malignant neoplastic disease that is the fourth most commonly occurring cancer in women worldwide. Since the introduction of angiogenesis inhibitors, treatments for recurrent and advanced cervical cancers have improved significantly in the past five years. However, the median overall survival in advanced cervical cancer is 16.8 months, with a 5-year overall survival rate of 68% for all stages, indicating that the effects of the treatment are still unsatisfactory. The development of a new treatment method is therefore imperative. Recently, in the clinical oncology field, remarkable progress has been made in immunotherapy. Immunotherapy is already established as standard therapy in some fields and in some types of cancers, and its clinical role in all areas, including the gynecology field, will change further based on the outcomes of currently ongoing clinical trials. This manuscript summarizes the results from previous clinical trials in cervical cancer and describes the ongoing clinical trials, as well as future directions.

引用

页数：13

共 35 条

[1] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[2] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[3] Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy [J].

Balermpas, Panagiotis ;

Martin, Daniel ;

Wieland, Ulrike ;

Rave-Fraenk, Margret ;

Strebhardt, Klaus ;

Roedel, Claus ;

Fokas, Emmanouil ;

Roedel, Franz .

ONCOIMMUNOLOGY, 2017, 6 (03)

[4] A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer [J].

Basu, Partha ;

Mehta, Ajay ;

Jain, Minish ;

Gupta, Sudeep ;

Nagarkar, Rajnish V. ;

John, Subhashini ;

Petit, Robert .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (04) :764-772

[5] Integrated genomic and molecular characterization of cervical cancer [J].

Burk, Robert D. ;

Chen, Zigui ;

Saller, Charles ;

Tarvin, Katherine ;

Carvalho, Andre L. ;

Scapulatempo-Neto, Cristovam ;

Silveira, Henrique C. ;

Fregnani, Jose H. ;

Creighton, Chad J. ;

Anderson, Matthew L. ;

Castro, Patricia ;

Wang, Sophia S. ;

Yau, Christina ;

Benz, Christopher ;

Robertson, A. Gordon ;

Mungall, Karen ;

Lim, Lynette ;

Bowlby, Reanne ;

Sadeghi, Sara ;

Brooks, Denise ;

Sipahimalani, Payal ;

Mar, Richard ;

Ally, Adrian ;

Clarke, Amanda ;

Mungall, Andrew J. ;

Tam, Angela ;

Lee, Darlene ;

Chuah, Eric ;

Schein, Jacqueline E. ;

Tse, Kane ;

Kasaian, Katayoon ;

Ma, Yussanne ;

Marra, Marco A. ;

Mayo, Michael ;

Balasundaram, Miruna ;

Thiessen, Nina ;

Dhalla, Noreen ;

Carlsen, Rebecca ;

Moore, Richard A. ;

Holt, Robert A. ;

Jones, Steven J. M. ;

Wong, Tina ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Kucherlapati, Raju ;

Hadjipanayis, Angela ;

Seidman, Jonathan ;

Kucherlapati, Melanie ;

Ren, Xiaojia ;

Xu, Andrew W. .

NATURE, 2017, 543 (7645) :378-+

[6]

Cancer IAfRo, CANC FACT SHEETS CER

[7] Genomics-and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors A Review [J].

Dijkstra, Krijn K. ;

Voabil, Paula ;

Schumacher, Ton N. ;

Voest, Emile E. .

JAMA ONCOLOGY, 2016, 2 (11) :1490-1495

[8] Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer [J].

Enwere, Emeka K. ;

Kornaga, Elizabeth N. ;

Dean, Michelle ;

Koulis, Theodora A. ;

Tien Phan ;

Kalantarian, Maria ;

Kobel, Martin ;

Ghatage, Prafull ;

Magliocco, Anthony M. ;

Lees-Miller, Susan P. ;

Doll, Corinne M. .

MODERN PATHOLOGY, 2017, 30 (04) :577-586

[9] The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance [J].

Feng, Yang-chun ;

Ji, Wen-li ;

Yue, Na ;

Huang, Yan-chun ;

Ma, Xiu-min .

CANCER MANAGEMENT AND RESEARCH, 2018, 10 :105-113

[10] PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas [J].

Franzen, Alina ;

Vogt, Timo J. ;

Mueller, Tim ;

Dietrich, Joern ;

Schroeck, Andreas ;

Golletz, Carsten ;

Brossart, Peter ;

Bootz, Friedrich ;

Landsberg, Jennifer ;

Kristiansen, Glen ;

Dietrich, Dimo .

ONCOTARGET, 2018, 9 (01) :641-650

← 1 2 3 4 →